Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug targets bone marrow failure

NCT ID NCT07712562

Not yet recruiting Disease control Sponsor: Dren Bio Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests an experimental drug called dibotatug (DR-01) in adults with bone marrow failure syndromes, including severe aplastic anemia. The goal is to see if the drug is safe and can improve blood cell counts. Participants receive dibotatug by IV infusion, and researchers monitor for side effects and treatment response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dibotatug (DR-01) given by IV infusion
What this could lead to
If successful, dibotatug could offer a new treatment option for people with bone marrow failure syndromes who have not responded to other therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aplastic anemia aplastic anemia Bone Marrow Failure Disorders bone marrow failure syndrome hematologic disorder leukocyte disorder pancytopenia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANEMIAS BONE MARROW FAILURE SYNDROMES NON-SEVERE APLASTIC ANEMIA SEVERE APLASTIC ANEMIA (SAA) SEVERE APLASTIC ANEMIA, REFRACTORY SEVERE APLASTIC ANEMIA, RELAPSE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dren Investigational Site

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dren Investigational Site

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dren Investigational Site

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dren Investigational Site

    Atlanta, Georgia, 30342, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dren Investigational Site

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dren Investigational Site

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dren Investigational Site

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dren Investigational Site

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dren Investigational Site

    Fairfax, Virginia, 22031, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dren Investigational Site

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.